VistaGen Therapeutics Inc. reported a research and development expense of $15.9 million for the three months ended September 30, 2025, up from $10.2 million in the same period in 2024. General and administrative expense was $4.4 million, compared to $4.2 million the previous year. As of September 30, 2025, the company had $77.2 million in cash, cash equivalents, and marketable securities. During the period, VistaGen completed the PALISADE-3 Phase 3 Public Speaking Challenge Study of fasedienol for acute treatment of social anxiety disorder, with topline results expected by year-end. The company also appointed Paul Edick to its Board of Directors and to its Audit and Compensation Committees.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113819333) on November 13, 2025, and is solely responsible for the information contained therein.